Allogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results Post author:andrewkaretas Post published:January 18, 2023 Post category:BCMA/Scientific Publications Continue ReadingAllogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results
Poster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 18, 2022 Post category:BCMA/Scientific Publications Continue ReadingPoster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Presentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 7, 2022 Post category:BCMA/Scientific Publications Continue ReadingPresentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Generation of Hypoimmunogenic Allogeneic CAR T Cells by Inactivation of Transcriptional Regulators of HLA Class I and II Genes Post author:andrewkaretas Post published:November 18, 2022 Post category:PLATFORM/Scientific Publications Continue ReadingGeneration of Hypoimmunogenic Allogeneic CAR T Cells by Inactivation of Transcriptional Regulators of HLA Class I and II Genes
Allogeneic CAR T Cells Derived From Younger Donor T Cells Have More Desirable T Cell Phenotype And Better in vitro Functionality Post author:andrewkaretas Post published:May 18, 2022 Post category:PLATFORM/Scientific Publications Continue ReadingAllogeneic CAR T Cells Derived From Younger Donor T Cells Have More Desirable T Cell Phenotype And Better in vitro Functionality
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma Post author:andrewkaretas Post published:April 20, 2022 Post category:CD70/Scientific Publications Continue ReadingPreclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma Post author:andrewkaretas Post published:April 18, 2022 Post category:CD70/Scientific Publications Continue ReadingPreclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors Post author:andrewkaretas Post published:March 18, 2022 Post category:BCMA/Scientific Publications Continue ReadingAllogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR Post author:andrewkaretas Post published:December 21, 2021 Post category:CD19/Scientific Publications Continue ReadingALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR
UNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 18, 2021 Post category:BCMA/Scientific Publications Continue ReadingUNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
